ArticleScience progress

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.

Weixing Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.